keyword
MENU ▼
Read by QxMD icon Read
search

Allogeneic transplant in myeloma

keyword
https://www.readbyqxmd.com/read/29661445/epidemiologic-profile-of-patients-transplanted-with-hematopoietic-stem-cells-in-a-reference-service-in-the-state-of-rio-grande-do-norte-brazil
#1
I Campos de Azevedo, M A Ferreira Júnior, L A Pereira de Aquino, A A de Oliveira, G K P Cruz, A I de Queiroz Cardoso, M L Ivo, V E P Santos
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) consists of the intravenous infusion of healthy hematopoietic stem cells to restore the medullary and immunologic function of patients affected by a series of hematologic, oncologic, immunologic, malignant and nonmalignant inherited or acquired diseases, with the possibility of cure or increase of disease-free survival. OBJECTIVE: To characterize the epidemiologic profile and the cases of death of patients who underwent HSCT...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29610955/prognostic-value-of-18-f-fdg-pet-ct-in-multiple-myeloma-patients-before-and-after-allogeneic-hematopoietic-cell-transplantation
#2
Antje Stolzenburg, Katharina Lückerath, Samuel Samnick, Martin Speer, Katharina Kneer, Jan-Stefan Schmid, Götz Ulrich Grigoleit, Susanne Hofmann, Ambros J Beer, Donald Bunjes, Stefan Knop, Andreas K Buck, Hermann Einsele, Constantin Lapa
PURPOSE: Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using18 F-2'-deoxy-2'-fluorodeoxyglucose ([18 F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT). METHODS: In this retrospective analysis, we evaluated [18 F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT...
April 2, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29555314/the-role-of-allogeneic-transplantation-for-multiple-myeloma-in-the-era-of-novel-agents-a-study-from-the-japanese-society-of-myeloma
#3
Koji Kawamura, Nobuhiro Tsukada, Yoshinobu Kanda, Takashi Ikeda, Akiyo Yoshida, Yasunori Ueda, Tadao Ishida, Kenshi Suzuki, Hirokazu Murakami
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered a potentially curative therapy for patients with multiple myeloma, the role of allo-HSCT remains unclear in the novel agent era. We conducted a retrospective study of 65 patients with multiple myeloma who underwent allo-HSCT at 19 institutions from 2009 to 2016. Patients received a median of 3 (range, 1 to 7) lines of prior therapy, including at least 1 novel agent, except for autologous HSCT. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 18...
March 16, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29540849/is-the-use-of-unrelated-donor-transplantation-leveling-off-in-europe-the-2016-european-society-for-blood-and-marrow-transplant-activity-survey-report
#4
Jakob R Passweg, Helen Baldomero, Peter Bader, Grzegorz W Basak, Chiara Bonini, Rafael Duarte, Carlo Dufour, Nicolaus Kröger, Jürgen Kuball, Arjan Lankester, Silvia Montoto, Arnon Nagler, John A Snowden, Jan Styczynski, Mohamad Mohty
Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic)...
March 14, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29523091/membranous-nephropathy-succeeding-autologous-hematopoietic-stem-cell-transplant-a-case-report
#5
Sanda Mrabet, Narjess Ben Aicha, Nihed Abdessayed, Moncef Mokni, Abdellatif Achour
BACKGROUND: Membranous nephropathy (MN), the leading cause of nephrotic syndrome in adults, is characterized by the deposition of subepithelial immune deposits. Most of the cases are primary, while only approximately 25% of the cases are secondary to some known diseases. Recently, MN has been considered to be a possible presentation of chronic graft-versus-host disease (GVHD) of the kidney in allogeneic hematopoietic stem cell transplantation (HSCT) patients. In autologous HSCT populations, there have been scarce reports of associated MN, as a result of immune dysregulation leading to systemic autoimmunity and miming chronic GVHD...
March 9, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29511407/autologous-graft-versus-host-disease-of-the-gastrointestinal-tract-in-patients-with-multiple-myeloma-and-hematopoietic-stem-cell-transplantation
#6
Muhammad B Hammami, Rebecca Talkin, Ahmad M Al-Taee, Martin W Schoen, Sagun D Goyal, Jin-Ping Lai
Multiple myeloma (MM) is the most common indication for autologous hematopoietic stem cell transplantation (HSCT) in North America. Despite occurring in up to 50% of patients undergoing allogeneic HSCT, the incidence of graft-versus-host disease (GVHD) after autologous HSCT is reportedly only 5-20%. Gastrointestinal involvement with graft-versus-host disease (GI GVHD) is a common and serious complication of allogeneic HSCT. GI GVHD after autologous transplant, which is referred to as autologous GVHD (auto-GVHD), has also been described...
February 2018: Gastroenterology Research
https://www.readbyqxmd.com/read/29427192/community-acquired-respiratory-infections-are-common-in-patients-with-non-hodgkin-lymphoma-and-multiple-myeloma
#7
Noa Lavi, Irit Avivi, Zipora Kra-Oz, Ilana Oren, Emilia Hardak
PURPOSE: Available data suggest that respiratory infections are associated with increased morbidity and mortality in patients hospitalized due to acute leukemia and allogeneic stem cell transplantation (allo-SCT). However, the precise incidence, risk factors, and severity of respiratory infection, mainly community-acquired, in patients with lymphoma and multiple myeloma (MM) are not fully determined. The current study aimed to investigate risk factors for respiratory infections and their clinical significance in patients with B cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) in the first year of diagnosis...
February 9, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29296873/tandem-autologous-allogeneic-hematopoietic-cell-transplantation-with-bortezomib-maintenance-therapy-for-high-risk-myeloma
#8
Damian J Green, David G Maloney, Barry E Storer, Brenda M Sandmaier, Leona A Holmberg, Pamela S Becker, Min Fang, Paul J Martin, George E Georges, Michelle E Bouvier, Rainer Storb, Marco Mielcarek
We evaluated tandem autologous/allogeneic hematopoietic cell transplantation followed by bortezomib maintenance therapy in a prospective phase 2 trial of treatment of high-risk multiple myeloma. The high-dose conditioning regimen for autologous hematopoietic cell transplantation consisted of melphalan 200 mg/m2 . The nonmyeloablative conditioning regimen for the allogeneic transplant involved low-dose total body irradiation (2 Gy) with or without fludarabine (30 mg/m2 × 3 days). Among the 31 patients enrolled, 26 (84%) proceeded to HLA-matched allogeneic hematopoietic cell transplantation at a median of 61 (range, 41-168) days following the autologous transplant...
November 14, 2017: Blood Advances
https://www.readbyqxmd.com/read/29290952/transient-paraproteinemia-after-allogeneic-hematopoietic-stem-cell-transplantation-is-an-underexplored-phenomenon-associated-with-graft-versus-host-disease
#9
Corinne C Widmer, Stefan Balabanov, Urs Schanz, Alexandre P A Theocharides
The clinical and biological relevance of a paraprotein that newly arises after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in non-myeloma patients is unknown. In this study, the incidence, the course, and the clinical impact of paraproteins found after allo-HSCT were investigated in a cohort of 383 non-myeloma patients. Paraproteinemia after allo-HSCT was more frequent (52/383 patients, 14%) than the reported incidence of monoclonal gammopathy of unknown significance (MGUS) in age-matched healthy subjects and, in contrast to MGUS, did not correlate with age...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29250696/nephrotic-syndrome-after-autologous-hematopoietic-stem-cell-transplantation-a-case-report
#10
Bogdan Obrişcă, Adriana Roxana JurubiŢă, Andreea Gabriella Andronesi, Mihaela Gherghiceanu, Gener Ismail, George Mitroi, Mihai Cristian Hârza
Nephrotic syndrome (NS) is a rare complication of hematopoietic cell transplantation (HCT) and is thought to represent a renal manifestation of chronic graft-versus-host disease (cGVHD). Glomerulopathies occur less often in recipients of autologous as compared to allogeneic HCT and, in this setting, renal pathology is less well characterized. This case report describes a 54-year-old man admitted for the evaluation of a nephrotic-range proteinuria. His past medical history included a ? light-chain secreting multiple myeloma (MM) for which he underwent autologous HCT...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/29217779/prognostic-significance-of-tumor-burden-assessed-by-whole-body-magnetic-resonance-imaging-in-multiple-myeloma-patients-treated-with-allogeneic-stem-cell-transplantation
#11
Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass
Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe. To study possible predictors of survival, 79 patients were investigated using whole-body magnetic resonance imaging to assess the visible tumor burden before and after allogeneic stem cell transplantation. Statistical analysis of clinical and imaging parameters included Cox regression models and distribution of survival time estimates (Kaplan-Meier method)...
February 2018: Haematologica
https://www.readbyqxmd.com/read/29179894/-preventative-and-therapeutic-relapse-strategies-after-allogeneic-hematopoietic-stem-cell-transplantation-guidelines-from-the-francophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#12
REVIEW
Nabil Yafour, Florence Beckerich, Claude Eric Bulabois, Patrice Chevallier, Étienne Daguindau, Cécile Dumesnil, Thierry Guillaume, Anne Huynh, Stavroula Masouridi Levrat, Anne-Lise Menard, Mauricette Michallet, Cécile Pautas, Xavier Poiré, Aurelie Ravinet, Ibrahim Yakoub-Agha, Ali Bazarbachi
Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory disease or with persistent molecular or radiological (PET-CT scan) residual disease. Within the frame of the 7th annual workshops of the francophone society for bone marrow transplantation and cellular therapy, the working group reviewed the literature in order to elaborate unified guidelines for the prevention and treatment of relapse after allo-HCT...
December 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29179517/a-phase-i-trial-of-nk-92-cells-for-refractory-hematological-malignancies-relapsing-after-autologous-hematopoietic-cell-transplantation-shows-safety-and-evidence-of-efficacy
#13
Brent A Williams, Arjun Datt Law, Bertrand Routy, Neal denHollander, Vikas Gupta, Xing-Hua Wang, Amélie Chaboureau, Sowmya Viswanathan, Armand Keating
Background: Autologous NK cell therapy can treat a variety of malignancies, but is limited by patient-specific variations in potency and cell number expansion. In contrast, allogeneic NK cell lines can overcome many of these limitations. Cells from the permanent NK-92 line are constitutively activated, lack inhibitory receptors and appear to be safe based on two prior phase I trials. Materials and Methods: We conducted a single-center, non-randomized, non-blinded, open-label, Phase I dose-escalation trial of irradiated NK-92 cells in adults with refractory hematological malignancies who relapsed after autologous hematopoietic cell transplantation (AHCT)...
October 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/29079457/autologous-allogeneic-hematopoietic-cell-transplantation-versus-tandem-autologous-transplantation-for-multiple-myeloma-comparison-of-long-term-postrelapse-survival
#14
Myo Htut, Anita D'Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, Edward Copelan, Siddhartha Ganguly, Mehdi Hamadani, Mohamed Kharfan-Dabaja, Hillard Lazarus, Cindy Lee, Kenneth Meehan, Taiga Nishihori, Ayman Saad, Sachiko Seo, Muthalagu Ramanathan, Saad Z Usmani, Christina Gasparetto, Tomer M Mark, Yago Nieto, Parameswaran Hari
We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29063955/novel-agent-based-salvage-autologous-stem-cell-transplantation-for-relapsed-multiple-myeloma
#15
MULTICENTER STUDY
Beatrice Anna Zannetti, Paola Tacchetti, Lucia Pantani, Barbara Gamberi, Patrizia Tosi, Serena Rocchi, Claudia Cellini, Sonia Ronconi, Annalisa Pezzi, Katia Mancuso, Ilaria Rizzello, Isola Caratozzolo, Marina Martello, Luca Dozza, Michele Cavo, Elena Zamagni
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months...
December 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29032267/long-term-follow-up-of-a-donor-versus-no-donor-comparison-in-patients-with-multiple-myeloma-in-first-relapse-after-failing-autologous-transplantation
#16
Francesca Patriarca, Benedetto Bruno, Hermann Einsele, Francesco Spina, Luisa Giaccone, Vittorio Montefusco, Miriam Isola, Chiara Nozzoli, Andrea Nozza, Fortunato Morabito, Paolo Corradini, Renato Fanin
We report the long-term clinical outcomes of a retrospective multicenter study that enrolled 169 patients with multiple myeloma (MM) in first relapse after failing autologous stem cell transplantation (SCT). After HLA typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom eventually underwent salvage allogeneic SCT (allo-SCT), were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immunomodulatory agents. At a median follow-up of 30 months (range, 2-180 months) for all patients and 110 months (range, 38-180 months) for surviving patients, 7-year progression-free survival (PFS) was 18% in the donor group and 0% in the no-donor group (hazard ratio [HR], 2...
February 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28967897/donor-t-cell-responses-and-disease-progression-patterns-of-multiple-myeloma
#17
M Eefting, L C de Wreede, P A Von dem Borne, C J M Halkes, S Kersting, E W A Marijt, H Putter, H Veelken, J Schetelig, J H F Falkenburg
Donor T-cells transferred after allogeneic stem cell transplantation (alloSCT) can result in long-term disease control in myeloma by the graft-versus-myeloma (GvM) effect. However, T-cell therapy may show differential effectiveness against bone marrow (BM) infiltration and focal myeloma lesions resulting in different control and progression patterns. Outcomes of 43 myeloma patients who underwent T-cell-depleted alloSCT with scheduled donor lymphocyte infusion (DLI) were analyzed with respect to diffuse BM infiltration and focal progression...
December 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28959919/a-case-of-multiple-myeloma-with-navicular-bone-involvement
#18
Esra Yildizhan, Leylagul Kaynar, Nicolette Tiren, Ozlem Canoz, Bulent Eser
Multiple myeloma is a haematological disease caused by proliferation of malignant plasma cells in bone marrow. It frequently has lytic bone lesions. However, involvement of the small bones of the hands and feet is extremely rare. We report a unique multiple myeloma patient with first recurrence in navicular bone after allogenic stem cell transplantation.
November 2017: Scottish Medical Journal
https://www.readbyqxmd.com/read/28956132/vegf-angpt1-angpt2-and-mmp-9-expression-in-the-autologous-hematopoietic-stem-cell-transplantation-and-its-impact-on-the-time-to-engraftment
#19
Mateusz Nowicki, Agnieszka Wierzbowska, Roman Małachowski, Tadeusz Robak, Olga Grzybowska-Izydorczyk, Agnieszka Pluta, Anna Szmigielska-Kapłon
As a site of complicated interactions among cytokines, bone marrow niche has been the subject of many scientific studies, mainly in the context of the proteins influencing damage or recovery of endothelium after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we aimed at exploring mutual correlations of bone marrow niche cytokines involved in the homing and mobilization of hematopoietic stem cells, as well as in angiogenesis. The aim of our study was to evaluate levels of cytokines: VEGF, angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2), and matrix metalloproteinase 9 (MMP-9) during autologous HSCT and to examine their influence on hematological recovery...
December 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28900828/everyday-life-following-hematopoietic-stem-cell-transplantation-decline-in-physical-symptoms-within-the-first-month-and-change-related-predictors
#20
Aleksandra Kroemeke, Małgorzata Sobczyk-Kruszelnicka, Zuzanna Kwissa-Gajewska
PURPOSE: Lower quality of life, especially in the physical domain (Physical-QOL), is common in patients after hematopoietic stem cell transplantation (HSCT). However, few studies explore changes in the Physical-QOL, i.e., physical symptoms, in everyday life of patients following HSCT. The present study addresses this gap by examining patient daily physical symptoms and their predictors in terms of demographic and clinical characteristics. METHODS: Physical symptoms were reported by 188 patients (56...
January 2018: Quality of Life Research
keyword
keyword
13300
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"